[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-565773-105":53,"doc-detail-565773-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","annex-i-summary-of-product-characteristics-numelvi-veterinary-medicinal-product","ANNEX I - SUMMARY OF PRODUCT CHARACTERISTICS - Numelvi veterinary medicinal product","","ANNEX I provides the summary of product characteristics for Numelvi veterinary medicinal product tablets for dogs, detailing tablet strengths (4.8 mg, 7.2 mg, 21.6 mg, 31.6 mg), qualitative composition, appearance, and dividing score-line features. Clinical information covers target species, indications for pruritus and atopic dermatitis manifestations, contraindications based on hypersensitivity, and special safety precautions in younger or low-bodyweight dogs. It also includes adverse events reporting, pregnancy and lactation limitations, interaction statements, and oral once-daily dosing guidance by bodyweight bands.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/annex-i-summary-of-product-characteristics-numelvi-veterinary-medicinal-product/565773/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/annex-i-summary-of-product-characteristics-numelvi-veterinary-medicinal-product/565773.png","ImageObject",442,249,{"name":88,"@type":89},"LangkahRina","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-22","2026-10-13",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",7,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What are the indications for Numelvi tablets in dogs?","Question",{"text":109,"@type":110},"Numelvi is indicated for treating pruritus associated with allergic dermatitis, including atopic dermatitis, and for treating clinical manifestations of atopic dermatitis in dogs.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"Who should not use Numelvi?",{"text":114,"@type":110},"Numelvi must not be used in cases of hypersensitivity to the active substance or any excipients.",{"name":116,"@type":107,"acceptedAnswer":117},"How is Numelvi dosed and administered?",{"text":118,"@type":110},"Numelvi is for oral use and is administered once daily at or around feeding time, following the dosing table by the dog’s bodyweight band to achieve a target dose of 0.8–1.2 mg atinvicitinib/kg bodyweight.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},565773,1792087328,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":101},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ANNEX I  \nSUMMARY OF PRODUCT CHARACTERISTICS  \n1. NAME OF THE VETERINARY MEDICINAL PRODUCT  \nNumelvi 4.8 mg tablets for dogs  \nNumelvi 7.2 mg tablets for dogs  \nNumelvi 21.6 mg tablets for dogs  \nNumelvi 31.6 mg tablets for dogs  \n2. QUALITATIVE AND QUANTITATIVE COMPOSITION  \nEach tablet contains:  \nActive substances:  \nAtinvicitinib 4.8 mg  \nAtinvicitinib 7.2 mg  \nAtinvicitinib 21.6 mg  \nAtinvicitinib 31.6 mg  \nExcipients:  \n\n| Qualitative composition of excipients and other constituents |\n| --- |\n| Cellulose, microcrystalline |\n| Lactose monohydrate |\n| Sodium starch glycolate (type A) |\n| Tocofersolan |\n| Hydroxypropylcellulose |\n| Silica, colloidal anhydrous |\n| Magnesium stearate |\n\nWhite to off-white, oblong shaped tablets with one score-line on each side and marked with \"S\" (on the 4.8 mg tablets), \"M\" (on the 7.2 mg tablets), \"L\" (on the 21.6 mg tablets) or “XL”(on the 31.6 mg tablets) on each half of the top side.  \nThe tablets can be divided into two equal halves.  \n3. CLINICAL INFORMATION  \n3.1 Target species  \nDogs.  \n3.2 Indications for use for each target species  \nFor the treatment of pruritus associated with allergic dermatitis including atopic dermatitis in dogs. For the treatment of clinical manifestations of atopic dermatitis in dogs.  \n3.3 Contraindications  \nDo not use in cases of hypersensitivity to the active substance or to any of the excipients.  \n3.4 Special warnings  \nNone.  \n3.5 Special precautions for use  \nSpecial precautions for safe use in the target species:  \nSafety of this veterinary medicinal product has not been investigated in dogs younger than 6 months of age or weighing less than 3 kg bodyweight. Use of the veterinary medicinal product in younger animals or animals with a lower bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.  \nIt is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections (e.g., flea, Demodex mites), as well as any underlying causes (e.g., flea allergy, contact allergy, food allergy) of allergic and atopic dermatitis.  \nThe safety of the veterinary medicinal product has not been investigated in dogs with evidence of immune suppression, such as uncontrolled primary hypothyroidism or rickettsial disease, or with evidence of progressive malignant neoplasia.  \nTherefore, the use in such cases should be based on a benefit-risk assessment by the responsible veterinarian.  \nSpecial precautions to be taken by the person administering the veterinary medicinal product to animals:  \nWash hands thoroughly with soap and water immediately after use of the veterinary medicinal product.  \nSpecial precautions for the protection of the environment:  \nNot applicable.  \n3.6 Adverse events  \nDogs:  \n\n| Common\u003Cbr>(1 to 10 animals / 100 animals treated): | Emesis, Diarrhoea\u003Cbr>Lethargy, Anorexia |\n| --- | --- |\n\nReporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.  \n3.7 Use during pregnancy, lactation or lay  \nThe safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs.  \nPregnancy and lactation:  \nThe use is not recommended during pregnancy and lactation.  \nLaboratory studies in rats and rabbits have shown effects on prenatal development, inherent to the class of JAK inhibitors.  \nFertility:  \nThe use is not recommended in breeding animals.  \nLaboratory studies in male rats showed an effect on sperm counts and sperm motility.  \n3.8 Interaction with other medicinal products and other forms of interaction  \nNone known. No drug interactions were observed in field studies where the veterinary medicinal product was administered concomitantly with other veterinary","cbCaiqZk9I4MfxmG","https://ap.wps.com/l/cbCaiqZk9I4MfxmG","pdf",384119,20,"English","# 1. Name of the veterinary medicinal product\n## 2. Qualitative and quantitative composition\n## 3. Clinical information\n### 3.1 Target species\n### 3.2 Indications for use\n### 3.3 Contraindications\n### 3.4 Special warnings\n### 3.5 Special precautions for use\n### 3.6 Adverse events\n### 3.7 Use during pregnancy, lactation or lay\n### 3.8 Interaction with other medicinal products\n### 3.9 Administration routes and dosage","[{\"question\":\"What are the indications for Numelvi tablets in dogs?\",\"answer\":\"Numelvi is indicated for treating pruritus associated with allergic dermatitis, including atopic dermatitis, and for treating clinical manifestations of atopic dermatitis in dogs.\"},{\"question\":\"Who should not use Numelvi?\",\"answer\":\"Numelvi must not be used in cases of hypersensitivity to the active substance or any excipients.\"},{\"question\":\"How is Numelvi dosed and administered?\",\"answer\":\"Numelvi is for oral use and is administered once daily at or around feeding time, following the dosing table by the dog’s bodyweight band to achieve a target dose of 0.8–1.2 mg atinvicitinib/kg bodyweight.\"}]","ANNEX I - SUMMARY OF PRODUCT CHARACTERISTICS - Numelvi veterinary medicinal product | PDF",1791857964]